Trial Profile
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Niclosamide (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.
- 28 Nov 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jan 2024.
- 21 Apr 2023 Planned End Date changed from 1 Feb 2023 to 1 Dec 2023.